相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer
Alexandra Leary et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Bradley J. Monk et al.
LANCET ONCOLOGY (2021)
The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry
Hyeong In Ha et al.
OBSTETRICS & GYNECOLOGY SCIENCE (2021)
Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy
Yong J. Lee et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Revising the WHO classification: female genital tract tumours
Ian A. Cree et al.
HISTOPATHOLOGY (2020)
Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
Yong Jae Lee et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
Yeon Hee Park et al.
NATURE COMMUNICATIONS (2020)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data
Francesca Finotello et al.
GENOME MEDICINE (2019)
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
James W. Opzoomer et al.
FRONTIERS IN IMMUNOLOGY (2019)
A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
Jung-Yun Lee et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2019)
Changes in ovarian cancer survival during the 20 years before the era of targeted therapy
Jung-Yun Lee et al.
BMC CANCER (2018)
Combining immune Checkpoint inhibitors with Conventional Cancer Therapy
Yiyi Yan et al.
FRONTIERS IN IMMUNOLOGY (2018)
Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer
Hyun-Soo Kim et al.
GYNECOLOGIC ONCOLOGY (2018)
Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
S. J. L. Mesnage et al.
ANNALS OF ONCOLOGY (2017)
Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
Charlotte S. Lo et al.
CLINICAL CANCER RESEARCH (2017)
Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer
Maartje C. A. Wouters et al.
CLINICAL CANCER RESEARCH (2016)
Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Steffen Bohm et al.
CLINICAL CANCER RESEARCH (2016)
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies
Kevin E. Fisher et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma
Steffen Boehm et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Sean Kehoe et al.
LANCET (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer
Julie S. Nielsen et al.
CLINICAL CANCER RESEARCH (2012)
survcomp: an R/Bioconductor package for performance assessment and comparison of survival models
Markus S. Schroeder et al.
BIOINFORMATICS (2011)
The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors
Junzo Hamanishi et al.
CLINICAL IMMUNOLOGY (2011)
Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression
Renee Vermeij et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma
Martin Poelcher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
Blaise Clarke et al.
MODERN PATHOLOGY (2009)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
